RecruitingNot applicableNCT04119908
Blood
Glanzmann Thrombasthenia
Also known as GT, thrombasthenia of Glanzmann and Naegeli, ITGA2B/ITGB3 deficiency
Glanzmann thrombasthenia is a rare inherited platelet function disorder caused by biallelic mutations in ITGA2B or ITGB3 encoding the platelet integrin alphaIIbbeta3 (glycoprotein IIb/IIIa), the principal platelet surface receptor for fibri
ORPHA:849 ↗Gene ITGA2BGene ITGB3Prevalence Less than 1 in 1,000,000; higher in consanguineous populationsOnset Infancy; bleeding typically apparent with first hemostatic challengesAutosomal recessive
4
studies recruiting now
as of 7 Sept 2026
19
studies registered in total
as of 7 Sept 2026
2
countries with a recruiting site
as of 7 Sept 2026
22 Aug 2025
most recent study posted
among recruiting studies
Recruiting trials
RecruitingNCT06820515
ATHNdataset Registry
RecruitingPhase 2NCT07136857
Eptacog Beta in Glanzmann's (HeT_LFB-Strength-Study_FID531)
RecruitingNCT00230165
The Genetics and Functional Basis of Inherited Platelet, White Blood Cell, Red Blood Cell, and Blood Clotting Disorders.
Showing the 4 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.
Search all Glanzmann Thrombasthenia studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new Glanzmann Thrombasthenia study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
About Glanzmann Thrombasthenia
Glanzmann thrombasthenia is a rare inherited platelet function disorder caused by biallelic mutations in ITGA2B or ITGB3 encoding the platelet integrin alphaIIbbeta3 (glycoprotein IIb/IIIa), the principal platelet surface receptor for fibrinogen, which is essential for platelet aggregation and primary hemostasis. Three types are recognized: type I (less than 5% alphaIIbbeta3 expression), type II (10-20% expression), and type III (variant with dysfunctional receptor), all resulting in severely impaired platelet aggregation with all physiological agonists despite a normal platelet count. The condition causes lifelong mucocutaneous bleeding with particularly severe implications for surgical procedures, trauma, and childbirth.
Common clinical features
Lifelong mucocutaneous bleeding disproportionate to platelet countSevere menorrhagia in adolescent and adult femalesRecurrent epistaxis and gingival bleedingProlonged bleeding after minor wounds and dental proceduresGastrointestinal bleedingEcchymoses and purpuraNormal platelet count with absent platelet aggregation on aggregometryAbsence of clot retraction in type I
From Orphanet’s phenotype annotations (CC BY 4.0). Not a complete list.
Treatments being studied
1 in clinical development, from Open Targets (CC BY 4.0). Not medical advice.
Phase 1Eptacog Alfa (Activated) (Novoseven)
Before you apply
Things trial teams commonly ask about for Glanzmann Thrombasthenia. Not eligibility rules; those are set by each study.
- Platelet aggregometry showing absent aggregation with ADP, collagen, epinephrine, and thrombin receptor activating peptide (TRAP) but normal ristocetin-induced agglutination is diagnostic and required for trial enrollment.
- Alloantibody status against alphaIIbbeta3 from platelet transfusions is critical; patients with anti-alphaIIbbeta3 antibodies may be excluded from some trials but are specifically targeted in others testing novel hemostatic agents.
- Bleeding Assessment Tool (BAT) scores and surgical or obstetric bleeding history should be documented; trials evaluating recombinant activated factor VII or thrombopoietin agents require detailed baseline bleeding phenotype.
Related conditions
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).